ErlySign secures ₹16 Cr in funding for next-gen diagnostics 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection
ErlySign secures ₹16 Cr in funding for next-gen diagnostics 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection
ErlySign secures ₹16 Cr in funding for next-gen diagnostics 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection 'Big Whale' invests in Curo Biosciences Lumos Health Accelerator onboards startups in early cancer detection
Partner with us
Partner with us

Coming Soon…

The Future of early Cancer Detection

Introducing a revolutionary saliva-based CRISPR-powered test for detecting five cancers — early, easily, and accurately.

Detect 5 Cancers. In Just 1 Test.

Leverage the power of saliva and CRISPR to detect oral, breast, lung, pancreatic, and colorectal cancers — non-invasively, affordably, and in under 45 minutes.

CRISPR Precision Meets Daily Practice

The test is powered by a CRISPR-based RNA biomarker assay that identifies cancers at the molecular level. Each cancer type has unique upregulated biomarkers, detected using a fluorimetric reaction.

98%

Sensitivity

95%

Specificity

30 min

Test results

  • Works without lab infrastructure
  • No MRI, CT, or blood needed
  • Affordable and easy to scale
  • Enables large-scale community screenings

What Sets CRISPR test Apart

ErlySign’s latest diagnostic innovation is a compact, portable saliva testing kit. Built with three ergonomic components and optional microfluidic tech, it is designed for fast, field-ready, and multi- cancer detection — enabling healthcare access from metros to rural India.

Backed by Peer Reviewed Research

15-Min

Test Results

Quick, lab-free detection

Development of Quantifiable Assays for Detection of Hypersialylation in Oral Cancer Diagnosis.

Unlocking the potential: Cas13-based sensing system in early detection of micro-RNA biomarker.

Comparative detection of small RNAs in saliva using Cas13a from Leptotrichia wadei (LwCas13a) assay and real-time PCR. (Manuscript submitted).

Novel nucleic acid detection platform with Cas13a and Cas9 coupled reaction. (Manuscript under development).

Products

For Business

Connect with us

CURO Biosciences Pvt Ltd
House no. 1087,khamla road,Near Tajshree honda,
Ramkrishna nagar,Deo nagar Nagpur,Maharashtra 440015

inquiry@erlysign.com

Stay Updated with ErlySign

Get Started with ErlySign

Fill in your details to explore how your clinic, lab, or hospital can integrate saliva-based early detection effortlessly.